AU2002257114A1 - Treatment of malaria with farsenyl protein transferase inhibitors - Google Patents

Treatment of malaria with farsenyl protein transferase inhibitors

Info

Publication number
AU2002257114A1
AU2002257114A1 AU2002257114A AU2002257114A AU2002257114A1 AU 2002257114 A1 AU2002257114 A1 AU 2002257114A1 AU 2002257114 A AU2002257114 A AU 2002257114A AU 2002257114 A AU2002257114 A AU 2002257114A AU 2002257114 A1 AU2002257114 A1 AU 2002257114A1
Authority
AU
Australia
Prior art keywords
farsenyl
malaria
treatment
protein transferase
transferase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002257114A
Inventor
Viyyoor M. Girijavallabhan
Corey O. Strickland
Patricia C. Weber
William T. Windsor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2002257114A1 publication Critical patent/AU2002257114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2002257114A 2001-04-06 2002-04-04 Treatment of malaria with farsenyl protein transferase inhibitors Abandoned AU2002257114A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28209201P 2001-04-06 2001-04-06
US60/282,092 2001-04-06
US28310701P 2001-04-11 2001-04-11
US60/283,107 2001-04-11
PCT/US2002/010698 WO2002080895A2 (en) 2001-04-06 2002-04-04 Treatment of malaria with farsenyl protein transferase inhibitors

Publications (1)

Publication Number Publication Date
AU2002257114A1 true AU2002257114A1 (en) 2002-10-21

Family

ID=26961242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002257114A Abandoned AU2002257114A1 (en) 2001-04-06 2002-04-04 Treatment of malaria with farsenyl protein transferase inhibitors

Country Status (2)

Country Link
AU (1) AU2002257114A1 (en)
WO (1) WO2002080895A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US7585864B2 (en) 2004-12-13 2009-09-08 Schering Corporation Farnesyl protein transferase inhibitors and their use to treat cancer
CA2591123A1 (en) * 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
DE102005017116A1 (en) * 2005-04-13 2006-10-26 Novartis Ag Inhibitors of Inhibitors of Apoptosis Proteins (IAP)
EP2280008B1 (en) 2007-01-16 2013-05-29 Purdue Pharma L.P. Heterocyclic-substituted piperidines as orl-1 ligands
NZ580801A (en) 2007-05-10 2012-09-28 Bristol Myers Squibb Co Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
RU2488585C2 (en) 2007-08-31 2013-07-27 Пэдью Фарма Л.П. Substituted quinoxaline-type piperidine compounds and use thereof
CN110627770A (en) 2013-11-18 2019-12-31 福马疗法公司 Tetrahydroquinoline compositions as BET bromodomain inhibitors
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
WO2023143389A1 (en) * 2022-01-29 2023-08-03 江苏恒瑞医药股份有限公司 Fused heterocyclic compound, preparation method therefor, and medical application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives
JP3264388B2 (en) * 1992-12-28 2002-03-11 ポーラ化成工業株式会社 Drugs against drug-resistant pathogenic microorganisms
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
WO1998011098A1 (en) * 1996-09-13 1998-03-19 Schering Corporation Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
CN1266433A (en) * 1997-06-17 2000-09-13 先灵公司 Benzpyrido cycloheptane compounds useful for inhibition of franesyl protein transferase
EE200100118A (en) * 1998-08-27 2002-06-17 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
ID29065A (en) * 1998-12-18 2001-07-26 Schering Corp TRANSFERAGE PROTEIN FARNESIL OBSTACLES
JP2002533336A (en) * 1998-12-18 2002-10-08 シェーリング コーポレイション Tricyclic farnesyl protein transferase inhibitors
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
WO2002080895A2 (en) 2002-10-17
WO2002080895A3 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AU2002362197A1 (en) Method of stabilizing protein
AU2002213485A1 (en) Inhibitors of protein kinases
AU2002310187A1 (en) Inhibitors of protein kinase for the treatment of disease
AU2002251266A1 (en) Inhibitors of akt activity
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AU2002363005A1 (en) Derivatives of uk-2a
AU2002257936A1 (en) Methods of well treatment
AU2002236813A1 (en) Treatment of malaria with farnesyl protein transferase inhibitors
AU2002343356A1 (en) Antisense modulation of protein kinase r expression
AU2003252072A1 (en) Modulation of protein kinase c-iota expression
AU2002256085A1 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2002257114A1 (en) Treatment of malaria with farsenyl protein transferase inhibitors
MXPA03009257A (en) Isoxaxole derivatives as inhibitors of src and other protein kinases.
AU2002306734A1 (en) Inhibitors of plasmepsins
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002304626A1 (en) Sterilization of surfaces
AU2002254375A1 (en) Inhibitors of prenyl-protein transferase
AU2002354363A1 (en) Method of activating protein
AU2002305868A1 (en) Inhibitors of reggamma
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
AUPR731901A0 (en) Method of treatment
AU2002342715A1 (en) Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
AU2002304733A1 (en) Amino-aza-cyclohexanes for the treatment of malaria
WO2003016502A9 (en) Tramdorins and methods of using tramdorins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase